Company / Operating Cash Flow
Fulcrum Therapeutics, Inc. Operating Cash Flow History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$60.1M
FY2025
5-year range
-$97.0M / -$2.2M
FY2021-FY2025
Trend
-2608.1%
vs FY2024
Sector context
#100 of 216
Health Care
What the data says
Operating Cash Flow changed -2608% YoY in FY2025, a notable deviation from the 7-year average annual change of -384%.
Based on SEC 10-K filings.
-$60M in FY2025.
Improved from -$91M to -$60M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#100 of 216 in Health CareTop 46% of 216This company -$60.1M Sector average $658.7M
▼
-109.1% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow decreased 2608.1% year-over-year.
- Ranks #100 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2024.
- Lowest operating cash flow in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 8.44 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$60.1M | -2608.1% |
| FY2024 | -$2.2M | +97.6% |
| FY2023 | -$91.0M | +6.3% |
| FY2022 | -$97.0M | -23.7% |
| FY2021 | -$78.5M | -46.3% |
| FY2020 | -$53.7M | -35.9% |
| FY2019 | -$39.5M | -75.0% |
| FY2018 | -$22.6M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026